InterFace panelists share their strategies for meeting market challenges
By John B. Mugford

The development panel at the Sept. 16-17, 2026, InterFace Healthcare Real Estate conference in Dallas included (from left to right): David Braunstein, managing director of investments, Rethink Healthcare Real Estate; Henry Johnson, VP of national client development, Catamount Constructors; Jim Hartmann, executive VP of development, NexCore Group; Ken Henry, senior VP of development, PMB; Matt Mattox, executive VP of construction and development, Catalyst Healthcare Real Estate; and moderator Murray W. Wolf, publisher and founder, HREI. (Photo courtesy of InterFace Conference Group)
Although the pace of traditional medical outpatient building (MOB) construction remains sluggish, developers are finding other opportunities, including more specialized higher-acuity MOBs, build-to-suit facilities and medical conversion projects.
That was one of the key takeaways from a panel of industry experts at the recent InterFace Healthcare Real Estate (HRE) conference in Dallas. The session, titled “The Development Pipeline: What’s Being Built, Where and For Whom?” included:
■ David Braunstein, managing director of investments for white Plains, N.Y.-based Rethink Healthcare Real Estate;
■ Jim Hartmann, executive VP of development with Denver-based NexCore Group LLC;
■ Ken Henry, senior VP of development with San Diego-based PMB;
■ Henry Johnson, VP of national client development with Lakewood, Colo.-based Catamount Constructors; and
■ Matt Mattox, executive VP of construction and development with Pensacola, Fla.-based Catalyst Healthcare Real Estate.
The discussion was moderated by Murray W. Wolf, founder and publisher of Healthcare Real Estate Insights (HREI).
Mr. Wolf set the stage by sharing some of the most recent market data, courtesy of the HRE research firm Revista and its RevistaMed service. He noted that
The full content of this article is only available to paid subscribers. If you are an active subscriber, please log in. To subscribe, please click here: SUBSCRIBE




